| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
| Targets |
2,6-Di-tert-butyl-4-methylpyridine has demonstrated notable activity with respect to total cholesterol levels in pharmacological studies. The compound exhibits strong antioxidant properties and is used to inhibit oxidative stress in biological systems. It interacts with various enzymes, proteins, and other biomolecules. The compound's tert-butyl groups provide steric hindrance that may influence its interactions with biological targets. Its hypolipidemic activity suggests potential for treating lipid disorders.
|
|---|---|
| ln Vitro |
2,6-di-tert-butyl-4-methylpyridine is employed to produce enol triflate using triflate from ketones. It is also employed in the diastereoselective synthesis of β-thiomannopyranosides, as a base in the PtCl4-catalyzed cyclic reaction of homopropargyl azide derivatives, and in the synthesis of 1,2-dihydro-2-silanaphthalene derivatives.
In vitro, 2,6-di-tert-butyl-4-methylpyridine exhibits strong antioxidant properties. It is used to inhibit oxidative stress in various biological systems. The compound is employed to generate enol triflates from ketones using triflate. It is used as a biochemical reagent in life science research. The compound's activity against oxidative stress makes it valuable for studying cellular signaling pathways and biomolecule stability. Cellular assays typically evaluate its antioxidant activity. |
| ln Vivo |
In vivo, 2,6-di-tert-butyl-4-methylpyridine has demonstrated notable activity with respect to total cholesterol levels in pharmacological studies. The compound's hypolipidemic activity suggests potential for therapeutic applications in lipid disorders. It is classified for research use only and is not intended for human or veterinary applications. The compound's antioxidant properties may contribute to its in vivo effects. Specific in vivo data for therapeutic applications is limited in the public literature.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 2,6-di-tert-butyl-4-methylpyridine typically evaluate its antioxidant activity or enzyme interactions. A standard assay protocol involves incubating the compound with relevant enzymes or cellular systems in appropriate buffer systems. The compound is dissolved in DMSO and diluted to working concentrations (typically 1-100 μM). Antioxidant activity is measured using DPPH, ABTS, or FRAP assays. Enzyme activity and binding affinity are assessed using standard biochemical techniques. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for 2,6-di-tert-butyl-4-methylpyridine typically evaluate its antioxidant activity and effects on oxidative stress. A standard protocol involves culturing appropriate cell lines in growth medium at 37°C with 5% CO₂. Cells are treated with varying concentrations of the compound (typically 1-100 μM). Oxidative stress is induced using H₂O₂ or other oxidants. Cellular reactive oxygen species levels are measured using fluorescent probes such as DCFH-DA. Cell viability is assessed using MTT or similar assays. IC₅₀ values are calculated from dose-response curves.
|
| Animal Protocol |
In vivo animal studies for 2,6-di-tert-butyl-4-methylpyridine have been conducted to evaluate its hypolipidemic activity. Pharmacological tests demonstrated notable activity with respect to total cholesterol levels in phase I studies. The compound is classified for research use only and is not intended for human or veterinary applications. Dosing and administration protocols would depend on the specific research objectives. The compound's antioxidant properties may contribute to its in vivo effects.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 2,6-di-tert-butyl-4-methylpyridine is limited, as it is primarily a research reagent. The compound has a molecular weight of approximately 205.34 g/mol. It is stored as a solid at room temperature. As a pyridine derivative with tert-butyl groups, the compound has high lipophilicity. The compound's steric hindrance may influence its metabolic clearance. Specific ADME data is not available in the public literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2,6-di-tert-butyl-4-methylpyridine is limited, as it is primarily a research reagent. The compound is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored in a dry, cool place away from incompatible materials. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values or detailed toxicological profiles are available in the public domain.
|
| Additional Infomation |
2,6-Di-tert-butyl-4-methylpyridine (DTBMP, CAS 38222-83-2) is a biochemical reagent with strong antioxidant properties. It has demonstrated hypolipidemic activity in pharmacological studies. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. It is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent. Its applications are limited to research.
|
| Molecular Formula |
C14H23N
|
|---|---|
| Molecular Weight |
205.34
|
| Exact Mass |
205.183
|
| CAS # |
38222-83-2
|
| PubChem CID |
98898
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
233.0±0.0 °C at 760 mmHg
|
| Melting Point |
33-36 °C(lit.)
|
| Flash Point |
83.9±0.0 °C
|
| Vapour Pressure |
0.1±0.4 mmHg at 25°C
|
| Index of Refraction |
1.480
|
| LogP |
4.56
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
15
|
| Complexity |
184
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1
|
| InChi Key |
HVHZEKKZMFRULH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H23N/c1-10-8-11(13(2,3)4)15-12(9-10)14(5,6)7/h8-9H,1-7H3
|
| Chemical Name |
2,6-ditert-butyl-4-methylpyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8700 mL | 24.3499 mL | 48.6997 mL | |
| 5 mM | 0.9740 mL | 4.8700 mL | 9.7399 mL | |
| 10 mM | 0.4870 mL | 2.4350 mL | 4.8700 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
